T HE RODENT placenta produces a family of proteins that include structural and functional homologs of pituitary PRL referred to as placental lactogens (PLs; 1, 2). PL-I, PL-I variant @'L-Iv), and PL-II possess PRL-like actions and are produced by trophoblast giant cells in a highly coordinated pattern during the development of the rat placenta (3-13). PL-I is expressed from implantation until midgestation, whereas PL-II is expressed from midgestation until parturition (6, 7, 10, 14) . PL-Iv is expressed during the latter half of gestation by trophoblast giant cells and also by another population of trophoblast cells referred to as spongiotrophoblast cells (11, 12) .
The actions of PL-I have been primarily studied via the generation of recombinant PL-I in Chinese hamster ovary (CHO) cells (5, 9). PL-I binds to PRL receptors (15, 16) and possesses a number of actions previously attributed to pi-tuitary PRL. These activities include stimulation of rat Nb2 lymphoma cell proliferation (4, 9), mouse mammary gland epithelial cell cw-lactalbumin and insulin-like growth factor binding protein (29 kDa IGFBP) biosynthesis (5, 17), islet B-cell proliferation, and insulin secretion (18), and luteal cell progesterone production (19) and the inhibition of pituitary PRL secretion (20) . PL-I is equipotent with pituitary PRL and the predominant lactogen of midgestation.
The biological activities of PL-Iv have been investigated with SDS-gel electrophoresis purified PL-Iv and heterologously expressed CHO cell recombinant 13) . Both preparations are capable of stimulating rat Nb2 lymphoma cell proliferation; however, neither is as potent as pituitary PRL (12, 13) . Recombinant PL-Iv is also capable of competing with pituitary PRL for PRL receptors, again at a reduced potency (13). Our current information suggests that PL-Iv is a functional homolog of pituitary PRL with somewhat reduced biological potency.
The actions of PL-II have been studied with native PL-II purified from either the mouse, rat, or hamster placenta (21-24). PL-II was originally characterized based on its ability to bind PRL receptors and mimic PRL biological activities (15, 16, (21) (22) (23) (24) (25) . Among the spectrum of PL-II actions resembling pituitary PRL are stimulation of a variety of cellular processes, including: rat Nb2 lymphoma cell proliferation (26), mouse mammary gland, epithelial cell cr-lactalbumin, and IGFBP (29 kDa) biosynthesis (17, 24, 27) , islet B-cell proliferation and insulin secretion (18), and luteal cell progesterone production (19). PL-II is equipotent with PRL and is the most prominent circulating lactogenic hormone of the latter half of pregnancy.
Recently, another rat PL, related to PL-I and PL-Iv, was identified and termed PL-I mosaic (PL-Im; 28). The expression pattern of PL-Im corresponds to the expression pattern of PL-I (28). Additional relationships of PL-Im to PL-I and the role of PL-Im in the physiology of pregnancy have not been determined.
The Rcho-1 trophoblast cell line has proven to be a useful model for studying the trophoblast giant cell lineage and the PLs they synthesize. Several years ago, Teshima and colleagues developed a procedure for experimentally generating rat choriocarcinomas (29). These trophoblast tumors were found to be transplantable, possess significant endocrine effects on their hosts, and subsequently were shown to express PL-I (29-31). Cell lines with trophoblast characteristics were established from the choriocarcinomas (32, 33) . One of these cell lines, referred to as Rcho-1 trophoblast cells, consists of a homogenous population of trophoblast stem cells that proliferate or can be induced to differentiate depending upon the conditions of their culture (33,34). Rcho-1 trophoblast cell differentiation is incremental, recapitulating the normal ontogeny of trophoblast giant cell differentiationspecific gene expression, including the expression of members of the PRL gene family and steroid hydroxylases (33-37). PL-I and PL-II have been reported to be expressed by differentiating Rcho-1 trophoblast cells along with two other members of the family, PRL-like protein-A (PLP-A) and 34 ). Differentiation appears restricted to the trophoblast giant cell lineage in that Rcho-1 trophoblast cells are not capable of expressing spongiotrophoblast-restricted genes (33, 38).
The present study was undertaken to resolve significant uncertainties regarding PLs in Rcho-1 trophoblast cells. An accurate assessment of which members of the PL-I subfamily (PL-I, PL-Im, and PL-Iv) are present in Rcho-1 trophoblast cells has not been accomplished. Available antibodies and nucleotide probes cannot discriminate among PL-I, PL-Im, and PL-Iv. The identity of the PL-I subfamily members in Rcho-1 trophoblast cells have been based on the sizes of PL-I immunoreactive proteins and their temporal appearance during in vitro differentiation. In this report, we show that the Rcho-1 PL-I corresponds to PL-Im. PL-Iv and PL-II were also identified in Rcho-1 cells and possess characteristics identical to their previously described placental counterparts. We further demonstrate that recombinant Rcho-1 PL-I and PL-II are functional PRL homologs. RT-PCR was performed with primers specific for Rcho-1 PL-I, rat PL-Iv, for the originally described PL-I, or rat p-actin (see Fig. 1 ). RT-PCR was performed according to the manufacturer's instructions (Superscript preamplification system for first strand cDNA synthesis kit, Life Technologies).
Five micrograms of total RNA samples and 0.5 Kg of oligo (deoxythymidine) were used for the reverse transcriptase reaction.
The PCR reaction was performed for 30 cycles (denature: 94 C for 1 min; annealing: 60 C for 2 min; extension: 72 C for 2 min). Amplified products were subcloned into the pGEM-T vector ( Total RNA was extracted from differentiated Rcho-1 trophoblast cells and choriovitelline placental tissue (isolated from day 11 of gestation) with the TRIzol Reagent. RT-PCR was performed with primers specific for Rcho-1 PL-I (nresent studv) and for the oriainallv described PL-I (10; data from phmer set No. i is shown), or raF&ac&n (see Fig.  1 ). PCR.amplificatibn of products from a rat genomic library with mimers for Rcho-1 PL-I or for the oriainallv identified PL-I was also evaluated. Amplified products were $ectrophoretically separated in 1% agarose gels stained with ethidium bromide transferred to nylon membranes and probed with a [32Pl-labeled Rcho-1 PL-I cDNA. Please note that the Rcho-1 PL-I was identified in Rcho-1 trophoblast cell midgestation choriovitelline placental tissues and from the rat genomic library whereas the original PL-I (10) amplification product was not generated from any of the sources. terone (50 rig/ml). At the termination of culture, proliferation was assessed by DNA fluorometric assay using cell standards (56).
Statistical analysis
The data were analyzed by ANOVA. The source of variation from significant F ratios was determined with the Newman-Keuls multiple comparison test (57).
Results
Isolation and characterization of Rcho-1 trophoblast cell PL-I and PL-II cDNA clones A cDNA library representing differentiated Rcho-1 trophoblast cells was generated. The sizes of cDNAs contained in the library ranged from 300bp to 10 kilobase pairs. The titer of the library was 4.2 X lo8 pfu/ml consisting of greater than 95% recombinant phages. Screening of the cDNA library (5 x lo5 pfu) for PL-I and PL-II resulted in the identification of several hundred positive plaques. Five positive PL-I plaques and six positive PL-II plaques were selected for in vim excision. pBK-CMY phagemid clones generated from in viva excision were tested with several different restriction enzymes. Three of the PL-I clones (PL-I-31,PL-I-33, PL-I-35) and four of the PL-II clones (PL-1131, PL-11-32, PL-11-33, PL-11-35) showed similar restriction maps, respectively. PL-I-33 and PL-II-33 were selected for further analysis. RT-PCR was performed with primers specific for rat PL-Iv (13) or rat p-actin (see Fig. 1 ). Amplified products were electrophoretically separated in 1% agarose gels stained with ethidium bromide transferred to nylon membranes and probed with a [32Pl-labeled PL-Iv cDNA. The rat p-actin amplified product was detected by ethidium bromide staining. Please note that PL-Iv products were specifically amplified from differentiated Rcho-1 trophbblast cells and-from the junctional zone of the chorioallantoic placenta. The identity of the amplified products were verified by nucleotide sequencing.
Sequence analysis of three independent
Rcho-1 PL-I cDNAs indicated that they significantly differed from the previously reported PL-I sequence (10) but more closely resembled a related cDNA referred to as PL-I mosaic (PL-Im; 28). Coding regions for Rcho-1 PL-I and PL-Im were identical. Forty-four nucleotides of Rcho-1 PL-I 5'-untranslated sequence were identified in the cDNAs (5'-agatttcctggctgggagctacactgtcctggatctgctcagaaATG-3') not previously reported in the PL-Im sequence. Two other single base differences were noted in 3' untranslated nucleotide sequence and have been submitted to GenBank. Rcho-1 PL-I transcripts could be detected in Rcho-1 trophoblast cells and normal developing placental tissue by RT-PCR; however, the previously reported PL-I transcript could not be identified from the same sources by RT-PCR (Fig. 2) . Furthermore the Rcho-1 PL-I gene was amplified from a rat genomic library with the same set of primers (Fig. 2) . We were not successful in amplifying any products from the rat genomic library with either set or combination of primers designed to detect the originally reported PL-I (Fig. 2) . Detection of amplified products was determined by ethidium bromide staining and Southern analysis with exposure of x-ray film for extended time periods. Given these results, we reexamined the original PL-I cDNA (10) by PCR and nucleotide sequence analyses. The sequence differed from the original report (10) and was found to be identical to the Rcho-1 PL-I (present study) and PL-Im cDNA (28) clones. Thus, PL-I, Rcho-1 PL-I, and PL-Im are equivalent and should be referred to as PL-I.
Rcho-1 PL-II cDNA sequences were virtually identical to the published PL-II sequence (3; data not shown). An additional 43 nucleotides of PL-II 5' untranslated sequence plus the translation start site were identified (5'-aagcagtctagtgttgtctccacttcgagaactcctcaaagATG-3').
The ATG start site replaces the initial GTG (valine) of the originally published PL-II sequence (3). One additional difference was noted in 3' flanking nucieotide sequence and has been submitted to GenBank.
PL-Iv was specifically amplified by RT-PCR from differentiated (day 9 of culture) but not undifferentiated (day 1 of culture) Rcho-1 trophoblast cells (Fig. 3) . The nucleotide sequence of the amplified Rcho-1 PL-Iv product was identical to the previously published PL-Iv sequence (13; data not shown).
Chromosomal assignment
The Rcho-1 PL-I gene was localized using somatic cell hybrids that segregate rat chromosomes. PCR-based identification of the R&IO-1 PL-I gene in the cell hybrids cosegregated with rat chromosome 17. Discordant clones were not observed. Independent discordant clones for the other rat chromosomes are shown in Table 1 . The data is consistent with the localization of the Rcho-1 PL-I gene to chromosome 17 of the rat genome. (Fig. 4) .
and PL-II (bottom panel) by Western blot analysis. Samples were separated by PAGE in 12.5% gels under reducing conditions. Proteins from the gels were electrophoretically transferred to nitrocellulose and probed with polyclonal antibodies specific to PL-I or PL-II. Immune comolexes were detected using the enhanced chemiluminescence system as previously described:Please note the bands in each blot migrating near the 66 M, standard are nonspecific. M, standards (X 10m3) are shown. a + and -= presence or absence of the rat gene, respectively. b+ = rat chromosome present in more than 55% of the metaphases; (+) = rat chromosome present in 25-55% of the metaphases; (-) = rat chromosome present in less than 25% of the metaphases; -= rat chromosome absent.
' When a chromosome was present in less than 25% of the metaphases ( -in parentheses), the hybrid in question was not taken in account to establish the number of discordancies for that particular chromosome. Biological actions of recombinant Rcho-1 PL-I and PL-II Concentrated conditioned medium enriched for either recombinant Rcho-1 PL-I or PL-II significantly stimulated the proliferation of lactogen-dependent rat Nb2 lymphoma cells, whereas conditioned medium generated from parent HRP-1 cells did not significantly modify the growth pattern of the Nb2 lymphoma cells (Fig. 5) . The actions of recombinant PL-I and PL-II were dose dependent and closely mimicked the action of ovine PRL (Fig. 5) . Concentrated conditioned medium containing either recombinant Rcho-1 PL-I or PL-II also significantly stimulated the proliferation of mouse mammary epithelial cells (Fig. 6 ). Parent HRP-1 cell conditioned medium did not significantly influence the behavior of the mouse mammary epithelial cells (Fig. 6) . The actions of recombinant Rcho-1 PL-I and PL-II were dose dependent and also synergistic with the addition of progesterone (Fig. 6 ). Mammary epithelial cell responses to recombinant Rcho-1 PL-I and PL-II were similar to those previously reported for mammary epithelial cell responses to pituitary PRL (55).
Discussion
Rcho-1 trophoblast cells have developed into a valuable model system for studying trophoblast cell biology. In this report, we have specifically identified and characterized PLs produced by Rcho-1 trophoblast cells. PL expression in Rcho-1 trophoblast cells is differentiation dependent and is represented by three different members of the placental PRL gene family. Two constituents of the PL-I subfamily and PL-II are expressed by differentiating Rcho-1 trophoblast cells. Rcho-1 PL-Iv and PL-II were found to be identical to their previously characterized placental counterparts (3, 11-13; present study). Rcho-1 PL-I was distinctly different than the earlier reported PL-I (10) but was identical to PL-Im throughout its coding sequence (28). Thus, Rcho-1 PL-I appears to be equivalent to PL-Im. Upon further analysis, Rcho-1 PL-I/PL-Im was readily identified in normal developing placental tissues and a portion of its corresponding gene was amplified from a rat genomic library by PCR. In contrast, we were not successful in identifying the originally identified PL-I (10) from Rcho-1 trophoblast cells, midgestation placental tissue, the Rcho-1 cDNA library, or from a rat genomic library using various combinations of two different sets of PCR primers spanning distinct regions of the original PL-I sequence (present study). We anticipated that each of these sources should have been positive for the originally identified PL-I (10). Additionally, Rcho-1 / PL-Im possesses PRL-like biological actions similar to those previously reported for PL-I (5, 9; present study). These results prompted a reexamination of the original PL-I cDNA. Following PCR and nucleotide sequence analyses, we conclude that the original PL-I, Rcho-1 PL-I (present study), and PL-Im (28) each encode the same protein. The appropriate PL-I sequence is represented by the Rcho-1 PL-I/PL-Im sequence (28, present study). Thus, there are only two members of the PL-I subfamily (PL-I and PL-Iv) and PL-I is equivalent to Rcho-1 PL-I / PL-Im.
All of the presently identified genes corresponding to members of the rat PRL family (PRL, PL-Iv, PL-II, PLP-A, PLP-B, PLP-C, PLP-C variant, and decidual/ trophoblast PRL-related protein) and now PL-I have been assigned to chromosome 17 of the rat genome (2, 13, 42, 43, 58, 59 ). Human chromosome 6 and mouse chromosome 13 show conservation of synteny with rat chromosome 17 and contain human and mouse PRL family genes, respectively (60, 61). Specific linkage arrangements of the PRL family genes on their respective chromosomes have not been reported.
Recombinant rat PL-I and PL-II proteins were produced in the rat HRP-1 trophoendodermal stem cell line (present study). HRP-1 cells were originally selected as a host for the PL-I and PL-II expression vectors because they do not endogenously express PL-I, PL-II, or any other lactogenic hormone and are readily transplantable (50). Unfortunately, PL-I and PL-II expression did not continue following transplantation of the transfected HRP-1 cell populations beneath the kidney capsule (unpublished observations). Nontheless, under in vitro conditions, the proteins were expressed and exhibited biochemical, immunochemical, and biological characteristics consistent with previously published work on rat PL-I and PL-II (9,26,53). Processing of PL-I by HRP-1 cells was somewhat different than the processing of native PL-I by trophoblast giant cells. HRP-1 cell-derived recombinant PL-I exhibits a faster electrophoretic mobility than native PL-I. Similar differences have been reported for CHO cell-recombinant PL-I vs. native PL-I and are likely attributable to cellspecific glycosylation patterns (5). Trophoblast giant cellspecific carbohydrate modifications may relate, at least in part, to the longevity of PL-I in circulation. PL-I has an extended half-life (62), which compensates for the paucity of available trophoblast giant cells during early phases of pregnancy. As gestation progresses, PL-II expression is activated and PL-I expression is terminated (7). PL-II is not glycosylated, possesses a short half-life in circulation, and increases in expression as the placenta grows in size (3, 6, 53) .
Both recombinant PL-I and PL-II generated in HRP-1 cells possessed biological activities indicative of their functional relatedness to PRL. The recombinant hormones effectively stimulated the proliferation of rat Nb2 lymphoma cells consistent with previous reports for recombinant rat PL-I and native rat PL-II (9,26; present study). Mammotrophic actions of both recombinant PL-I and PL-II were also demonstrated for the first time and closely resembled mitogenic effects of PRL on mammary epithelial cells (55; present study). Pregnancy-specific control of mammary epithelial cell proliferation is thus dependent upon the coordinated expression of PRL, PL-I, and PL-II by the pituitary and placenta. These three PRL family members also affect mammary gland milk protein synthesis and IGFBP expression (17, 24, 27) . Most interestingly, the mitogenic actions of PRL, PL-I, and PL-II on mammary epithelial cells are significantly augmented by progesterone (55, present study). This synergism is particularly noteworthy in that PRL, PL-I, and PL-II are also prominent regulators of progesterone biosynthesis by the corpus luteum (19).
In summary, we have provided new insights into the biology of PLs expressed by the Rcho-1 trophoblast cell line. The information further validates the use of this important in vitro model for studies on the trophoblast giant cell lineage and the biology of members of the PRL gene family. 
